Lyell Immunopharma, Inc. (LYEL)
Upgrades & Downgrades
Latest LYEL news
Biotech ETF Tops in June: 5 Stocks That Outperform
30 June 2022
Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' "short squeeze" and investors' bar...
Lyell Immunopharma to Participate in Goldman Sachs Global Healthcare Conference
7 June 2022
SOUTH SAN FRANCISCO, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies f...
Goldman Sachs Has 5 Buy-Rated Stocks Under $10 With 100% to 700% Upside Potential
12 March 2022
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
Biotech IPOs Have Slowed to a Snail's Pace
17 February 2022
Sana Biotechnology Inc. ( SANA , Financial) and Lyel Immunopharma Inc. ( LYEL , Financial) are poster children for what's happening in the biotech initial public offering market. The two companies rai...
FDA Clears Lyell Immunopharma' LYL132 Trial For Solid Tumors
24 January 2022
The FDA has cleared Lyell Immunopharma Inc's (NASDAQ: LYEL) Investigational New Drug (IND) application to initiate a Phase 1 trial for LYL132 in solid tumors. LYL132 is an investigational T-cell recep...
Lyell Immunopharma to Participate in Morgan Stanley Global Healthcare Conference
8 September 2021
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients wi...
Lyell Immunopharma Reports Second Quarter 2021 Financial Results and Business Highlights
12 August 2021
SOUTH SAN FRANCISCO, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients wit...
Lyell Immunopharma shares fall in trading debut
17 June 2021
Shares of San Francisco-based Lyell Immunopharma Inc. , a clinical-stage biotech that is developing T cell therapies for solid tumors, stumbled in their trading debut Thursday, falling 2.2% at last ch...
3 Biotechs Plus a Mortgage Lender Go Public Today
17 June 2021
The companies are Verve Therapeutics, Lyell Immunopharma, iSpecimen and Angel Oak Mortgage.